Ask AI
ProCE Banner Activity

REZILIENT1: Zipalertinib in Patients With EGFR ex20ins–Mutated NSCLC After Prior Platinum-Based Chemotherapy ± Amivantamab

Conference Coverage
Slideset

The phase IIb REZILIENT1 trial showed promise with zipalertinib as a potential therapeutic option for EGFR ex20ins–mutated NSCLC in patients with progressive disease after platinum-based chemotherapy including those with or without previous exposure to amivantamab.

Released: June 09, 2025

Expiration: December 08, 2025

Continue Activity

Share

Provided by

Provided by Clinical Care Options, LLC

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca, Boehringer Ingelheim Pharmaceuticals, Inc., Daiichi Sankyo, Inc, Genentech, a member of the Roche Group, and PharmaMar.

AstraZeneca

Boehringer Ingelheim Pharmaceuticals, Inc.

Daiichi Sankyo, Inc.

Genentech, a member of the Roche Group

PharmaMar